Guzik Group

Information on Tomasz Guzik's research

profile image of Prof T Guzik

Tomasz Guzik, Chair of Cardiovascular Medicine 

Prof Tomasz Guzik research focuses on understanding how inflammation and oxidation intersect in vascular biology, especially in the context of hypertension. His group most important contributions include understanding the mechanisms of oxidative stress and vascular dysfunction in humans (Circ Res, 2000; Circulation, 2002; JACC; 2008; J Clin Invest, 2022) and, more recently, the defining novel role of inflammation and adaptive immunity in hypertension (J Exp Med, 2007; Circulation, 2020; Circ Res, 2020). His most recent work focused on identifying neuroimmune reflexes controlling atherosclerosis (Nature, 2022).

In 2021 he was recognised as a Highly Cited Scientist by Clarivate.  He published over 250 original studies with top cited papers receiving >1000 citations (WoS H factor – 65; with a total of 18900 citations).

His group is currently funded primarily by the European Research Council, European Commission and the British Heart Foundation.

Prof Guzik is an Editor-in-Chief of Cardiovascular Research, serves as a board member of the European Society of Cardiology, Chairperson of the European Society of Cardiology Research and EU Grants Committee, and a treasurer of the British Atherosclerosis Society.

 

Summary of research topic:

Drummond GR, Vinh A., Guzik TJ., Sobey C: Immune mechanisms of hypertension. Nature Rev Immunol, 2019, 19(8):517-532.

 

Top 5 most recent discovery papers:

 

  1. Szczepaniak P., Siedlinski M., Hodorowicz-Zaniewska D., Nosalski R, Mikolajczyk TP, Dobosz AM, Dikalova A, Dikalov S, Streb J, Gara K, Basta P, Krolczyk J, Sulicka-Grodzicka J, Jozefczuk E, Dziewulska A, Saju B, Laksa I, Chen W, Dormer J, Tomaszewski M, Maffia P., Czesnikiewicz-Guzik M, Crea F, Dobrzyn A, Moslehi J, Grodzicki T, Harrison DG, Guzik TJ: Breast cancer chemotherapy induces vascular dysfunction and hypertension through NOX4 dependent mechanism. J Clin Invest, 2022, 2022;132(13):e149117. doi: 10.1172/JCI149117.

Identification of mechanisms through which docetaxel may increase vascular risk long term through persistent vascular dysfunction depenedent on epigenetic regulation of Nox4

 

  1. Mohanta S, Peng L., Li Y., Yin C, Lu S, Sun T, Carnevale L, Perrotta M, Ma Z, Förstera B, Stanic K, Zhang C, Zhang X, Szczepaniak P, Bianchini M, Saeed B, Carnevale R, Hu D, Nosalski R, Pallante F, Beer M, Santovito D, Ertürk A, Mettenleiter TC, KluppB, Megens R, Steffens S, Pelisek J, Eckstein HH, Kleemann R, Habenicht L, Mallat Z, Michel JB, Bernhagen J, Dichgans M, D´Agostino G, Guzik TJ., Olofsson PS, Weber C., Lembo G, Carnevale D. Habenicht AJR: Neuroimmune cardiovascular interfaces form atherosclerosis brain circuits. Nature, 2022, 605(7908):152-159.

Discovery of Artery-Brain Circuits; Guzik team contribution – providing translational evidence for the presence of the components of ABCs in human vasculature; work on defining the brain structures involved in ABC reflex.

 

  1. Siedlinski M, Jozefczuk E, Xu X, Teumer A, Evangelou E, Schnabel RB, Welsh P, Maffia P, Erdmann J, Tomaszewski M, Caulfield MJ, Sattar N, Holmes MV, Guzik TJ.: White Blood Cells and Blood Pressure: A Mendelian Randomization Study. Circulation. 2020 Mar 9. doi: 10.1161/CIRCULATIONAHA.119.045102

Use of genetic tools to demonstrate relationships between lymphocytes and blood pressure in humans using UK Biobank population

 

  1. Nosalski R, Siedlinski M, Denby L, McGinnigle E, Nowak M, Nguyen Dinh Cat A, Medina-Ruiz L, Cantini M, Skiba D, Wilk G, Osmenda G, Rodor J, Salmeron-Sanchez M, Graham G, Maffia P, Graham D, Baker AH, Guzik TJ.: T Cell-Derived miRNA-214 Mediates Perivascular Fibrosis in Hypertension. Circ Res. 2020 Feb 17. doi: 10.1161/CIRCRESAHA.119.315428

First identification of a novel mechanism of perivascular fibrosis in hypertension that is T cell-dependent and pharmacologically targetable.

 

  1. Czesnikiewicz-Guzik M, Osmenda G, Siedlinski M, Nosalski R, Pelka P, Nowakowski D, Wilk G, Mikolajczyk TP, Schramm-Luc A, Furtak A, Matusik P, Koziol J, Drozdz M, Munoz-Aguilera E, Tomaszewski M, Evangelou E, Caulfield M, Grodzicki T, D'Aiuto F, Guzik TJ.: Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy. Eur Heart J. 2019, 40(42):3459-3470.

First evidence of causal relationship between periodontitis and cardiovascular disease in humans beyond observational studies

 

Top 5 clinical trials:

 

  1. Guzik TJ., Ramasundarahettige C., Pogosova N., Lopez-Jaramillo P., Dyal L., Berkowitz SD, Muehlhofer E., Bhatt DL., Fox KAA, Yusuf S, Eikelboom JWE: Rivaroxaban plus Aspirin in Obese and Overweight Patients with Vascular Disease in the COMPASS Trial. J Am Coll Cardiol., 2021 77(5): 511-525. (IF-20.6)

 

  1. Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S; COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Jan 20;391(10117):205-218.

 

  1. Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS Investigators.:  Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 2019 Sep;157(3):682-691.

 

  1. Eikelboom JW, Connolly S, Bosch J, Dagenais G, Hart  RG, Shestakovska O, R Diaz, M Alings, EM Lonn, S Anand, P Widimsky , M Hori, A Avezum , LS Piegas , KRH Branch , J Probstfield , DL Bhatt , J Zhu , Y Liang , AP Maggioni, P Lopez-Jaramillo , M O’Donnell , A Kakkar , KAA Fox, AN Parkhomenko , G Ertl , Stefan Störk , M Keltai , L Ryden , N Pogosova, AL Dans, F Lanas , PJ Commerford, C Torp, Guzik TJ , PB Verhamme , D Vinereanu , JH Kim , AM Tonkin , BS Lewis, C Felix, K Yusoff MBBS, PG Steg, KP Metsarinne, N Cook, F Misselwitz, E Chen, D Leong, S Yusuf. Rivaroxaban with and without aspirin in stable coronary or peripheral artery disease. N Engl J Med, 2017 Oct 5;377(14):1319-1330.

 

 

This article was published on